Pars Isotope Co products

Radiopharmaceutical

Pars Isotope - Model Lu-177-PSMA - Theranostic Radiopharmaceutical for Prostate Cancer Treatment

Lu-177-PSMA is a theranostic radiopharmaceutical designed for the treatment of metastatic prostate cancer. Employing the Peptide Receptor Radionuclide Therapy (PRRT) technique, it selectively targets and binds to prostate tumor cells, facilitating the destruction of malignant cells. This unique action stems from its characteristic as a gamma emitter, allowing not only for therapeutic intervention but also for imaging and monitoring of treatment progress. Ideal for precision oncology, Lu-177-PSMA combines targeted therapeutic effectiveness with diagnostic capabilities, playing a crucial role in managing advanced prostate cancer cases by enabling both treatment and detailed imaging follow-up.

Pars Isotope - Model F-18 FDG - Radiopharmaceutical for PET Imaging

FDG, or Fluoro Deoxy Glucose, is a pivotal radiopharmaceutical utilized in positron emission tomography (PET) imaging. This compound capitalizes on the principle of metabolic trapping to use a radioactive tracer to directly evaluate the body's metabolic functions. FDG's utilization in whole-body PET imaging substantially enhances the capabilities for cancer diagnosis and staging, supports the selection of appropriate treatment options, and facilitates the evaluation of therapeutic responses. Cancer, although typically originating within a single organ, is a systemic disease, with metastatic spread to additional organs posing significant challenges. FDG's application in rapid diagnosis and the quantitative assessment of metastases makes it a critical tool in medical imaging, offering insights that drive effective treatment strategies.